ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to ...

In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a price target of $8.00. The company’s shares closed ...